OBX.US Obsidian Therapeutics, Inc. Common Stock
- Market cap
- USD 776M
- P/E
- -
- P/B
- -
- ROE
- -40.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OBX.US undervalued?
Graham numberThe Graham number of Obsidian Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Obsidian Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Obsidian Therapeutics, Inc. Common Stock yet.
Obsidian Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Obsidian Therapeutics, Inc. Common Stock
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and …
Full company profileObsidian Therapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Obsidian Therapeutics, Inc. Common Stock annual financial statements
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | 0.00 | 0.00 | - |
| Operating Income | -91.3M | -106M | -112M |
| EBITDA | -89.7M | -104M | -111M |
| Net Income | -83.1M | -101M | -128M |
| EPS | -1.35 | -1.63 | -3.12 |
| Balance Sheet | |||
| Total Assets | 184M | 88.6M | 341M |
| Total Liabilities | 358M | 355M | 20.2M |
| Shareholders' Equity | -174M | -266M | 321M |
| Cash & Short-term Investments | 49.8M | 80.5M | 215M |
| Total Debt | - | 4.28M | 4.06M |
| Cash Flow | |||
| Operating Cash Flow | -75.0M | -90.4M | -112M |
| Capital Expenditure | 779K | 73.0K | 0.00 |
| Free Cash Flow | -75.8M | -90.5M | -112M |
| Ratios | |||
| ROE | - | - | -40.0% |
| ROA | -45.2% | -113.6% | -37.6% |
| Debt to Equity | - | - | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Obsidian Therapeutics, Inc. Common Stock dividends
Obsidian Therapeutics, Inc. Common Stock has not paid dividends in the last 5 fiscal years.
Who owns Obsidian Therapeutics, Inc. Common Stock
- Insiders 1.13%
- Institutions 56.10%
- Public & others 42.78%
- Shares outstanding 61.8M
- Free float 47.5M
Top funds holding OBX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.87M | 3.03% | 0.00% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 242K | 0.39% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 205K | 0.33% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 87.0K | 0.14% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 70.5K | 0.11% | 0.00% | Sep 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 61.9K | 0.10% | +0.02% | Oct 2026 |
| Schwab Total Stock Market Index | 32.6K | 0.05% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 31.5K | 0.05% | 0.00% | Sep 2026 |
| Schwab US Broad Market ETF | 28.4K | 0.05% | 0.00% | Oct 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 28.1K | 0.05% | 0.00% | Sep 2026 |
| JHVIT Health Sciences I | 19.4K | 0.03% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 17.2K | 0.03% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite ETF | 16.6K | 0.03% | 0.00% | Oct 2026 |
| EQ/T. Rowe Price Health Sciences IB | 13.6K | 0.02% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 1.55K | 0.00% | 0.00% | Aug 2026 |
| T. Rowe Price Innovation Leaders ETF | 635.00 | 0.00% | 0.00% | Oct 2026 |
| State Street Balanced Index K | 237.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding OBX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Spruce Street Capital LP | 1.25M | 2.02% | 0.00% | Sep 2026 |
| Pivotal bioVenture Partners Investment Advisor LLC | 860K | 1.39% | 0.00% | Sep 2026 |
Obsidian Therapeutics, Inc. Common Stock company profile
- Company name
- Obsidian Therapeutics, Inc. Common Stock
- Ticker
- OBX.US
- Exchange
- USA Stocks
- Listed since
- Jul 13, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 87
- Fiscal year end
- December
- Address
- 1030 Massachusetts Avenue, Cambridge, MA, United States, 02138
- Phone
- 781 806 6245
- Website
- obsidiantx.com
About Obsidian Therapeutics, Inc. Common Stock
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Obsidian Therapeutics, Inc. Common Stock management
8- Dr. Maria Fardis M.B.A., Ph.D.Executive Chairman of the Board · born 1968
- Dr. Madan Jagasia M.D., M.S.President, CEO & Director · born 1970
- Mr. Dana M. Alexander M.B.A.Chief Technical Officer · born 1976
- Dr. Parameswaran Hari M.D., M.S.Chief Medical Officer · born 1968
- Ms. Julie B. FederChief Financial Officer · born 1971
- Caroline CodeVice President of Corporate Development & Investor Relations
- Ms. Jennifer H. PetersonChief People Officer · born 1967
- Dr. Peter Barrett Ph.D.Secretary & Director · born 1953